Natalie Vokes, M.D.

Peer-Reviewed Articles

1. Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Hambelton GM, Pecci F, Makarem M, Gandhi MM, Garbo E, De Giglio A, Gagliano A, Sperandi F, Gelsomino F, Scalera S, Cipriani L, Marinelli D, Lamberti G, Shaverdian N, Haradon J, Nguyen T, Voligny E, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Rodig SJ, Pfaff K, Wang X, Rekhtman N, Sholl LM, Luo J, Johnson BE, Janne PA, Arvind R, Gainor JF, Maugeri-Sacca M, Ardizzoni A, Heist RS, Arbour KC, Schoenfeld AJ, Vokes NI, Awad MM. TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors. J Thorac Oncol:103610, 2026. e-Pub 2026. PMID: 41690367.
2. Waqas M, Bandyopadhyay R, Showkatian E, Muneer A, Zafar A, Alvarez FR, Marin MC, Li W, Jaffray D, Haymaker C, Heymach JV, Vokes N, Soto LMS, Zhang J, Wu J. The next layer: augmenting foundation models with structure-preserving and attention-guided learning for local patches to global context awareness in computational pathology. NPJ Precis Oncol, 2026. e-Pub 2026. PMID: 41639188.
3. Han X, Li W, Lin J, Li S, Saad MB, Kitsel Y, Heeke S, Hong L, Mohamed MQ, Le X, Vokes N, Godoy MC, Carter BW, Shroff GS, Eapen G, Byers LA, Vaporciyan AA, Gibbons DL, Heymach J, Wu CC, Zhang J, Wu J. Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer. Eur Radiol, 2025. e-Pub 2025. PMID: 41405691.
4. Li, H, Hong, L, Rocha, P, Bach, R, Solis Soto, LM, Rinsurongkawong, W, Zhang, B, Araujo, HA, Elamin, YY, Altan, M, Arrechedera, C, Zhou, J, Khan, KB, Lu, W, Young, E, Gay, CM, Cascone, T, Byers, LA, Skoulidis, F, Blumenschein, GR, Fossella, FV, Tsao, A, Vailati Negrao, M, Vokes, N, Wu, J, Tran, HT, Wistuba, II, Lee, JJ, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Le, X, Zhang, J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers 17(23), 2025. e-Pub 2025. PMID: 41375002.
5. Johri, S, Bi, K, Titchen, BM, Fu, J, Conway, J, Crowdis, J, Vokes, N, Fan, Z, Fong, L, Park, J, Liu, D, He, MX, Van Allen, EM. Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40025015.
6. Ackbarali, T, Vokes, N, Gainor, J, Ledezma, BA, Brahmer, JR, Borghaei, H. Confidence in patient-provider consideration of immunotherapy in a congested landscape. JCO Oncology Practice 21:80, 2025. e-Pub 2025.
7. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Chaib M, Yang Y, Wang B, Poteete A, Nilsson MB, Le X, Cascone T, Jaffray D, Navin N, Wang T, Byers LA, Gibbons DL, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST detects global and local biological structures in spatial transcriptomics datasets. Nat Cell Biol 27(11):2019-2031, 2025. e-Pub 2025. PMID: 41083603.
8. Salehjahromi M, Li H, Showkatian E, Saad MB, Qayati M, Ismail SM, Sujit SJ, Muneer A, Aminu M, Hong L, Han X, Heeke S, Cascone T, Le X, Vokes N, Gibbons DL, Toumazis I, Ostrin EJ, Antonoff MB, Vaporciyan AA, Jaffray D, Kay FU, Carter BW, Wu CC, Godoy MCB, Lee JJ, Gerber DE, Heymach JV, Zhang J, Wu J. Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients. Cancers (Basel) 17(21), 2025. e-Pub 2025. PMID: 41228201.
9. Singhi, EK, Sanchez, N, Vokes, N, Gibbons, DL, Altan, M, Rajaram, R, Heymach, JV, Kulkarni, S, Byers, LA. Improving lung cancer management through pre-visit liquid biopsy. JCO Oncology Practice 21:478, 2025. e-Pub 2025.
10. Saad MB, Showkatian E, Verma V, Al-Tashi Q, Aminu M, Xu X, Qayati Mohamed M, Salehjahromi M, Sujit SJ, Kitsel Y, Lin SH MD,, Liao Z, Gandhi S, Qian D, Jaffray D, Chung C, Vokes NI, Zhang J, Lee JJ, Heymach JV, Wu J, Chang JY. Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial. J Immunother Cancer 13(10), 2025. e-Pub 2025. PMID: 41052882.
11. Di Federico A, Wang K, Chen MF, Barsouk AA, Pagliaro A, Chen LN, Ogliari FR, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton GM, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi JV, Pecci F, Gelsomino F, Corassa M, Vokes NI, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad MM, Pabani A, Murray JC, Cappuzzo F, Garassino MC, Dagogo-Jack I, Riely G, Grant M, Herzberg BO, Ardizzoni A, Planchard D, Johnson BE, Langer CJ, Offin M, Negrao MV, Ricciuti B. First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol 26(10):1357-1369, 2025. e-Pub 2025. PMID: 41038185.
12. Zhang, B, Shah, K, Parma, M, Wang, K, Singhi, EK, Lewis, WE, Rivera, MJ, Altan, M, Pozadzides, JV, Le, X, Vokes, N, Fossella, FV, O'Brien, BJ, Wang, C, Tom, MC, Beckham, TH, Swanson, T, Bronk, JK, Lin, SH, Vega, MF, Jacome, J, Halliday, A, Vailati Negrao, M, Zhang, J, Gibbons, DL, Heymach, JV, Byers, LA, Gay, CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series. Journal of Thoracic Oncology 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
13. Hong L, Di Federico A, Liu B, Cooper AJ, Alessi JV, Clark P, Rinsurongkawong W, Young C, Li H, Qin K, Aminu M, Elamin Y, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee JJ, Le X, Wu J, Roy-Chowdhuri S, Routbort MJ, Futreal PA, Heymach JV, Awad MM, Schoenfeld AJ, Zhang J, Ricciuti B, Deng L, Vokes NI. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multi-Center Retrospective Study. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40716572.
14. Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X, Elamin YY, Altan M, Heeke S, Sheshadri A, Chang JY, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili S, Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun 16(1):6828, 2025. e-Pub 2025. PMID: 40707438.
15. Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, Ramkumar K, Paula AG, Pisegna M, McGrail DJ, Poteete A, Cho S, Do MT, Karimi A, Kong Y, Solanki A, Karmokar A, Floc'h N, Hughes A, Sargeant R, Young L, Shen L, Kar G, Keshvani C, Arrechedera C, Hernandez S, Schlacher K, Wang J, Iyer S, Conway J, Keddar MR, Milo M, de Toma I, Critchlow SE, Barrett JC, Cosaert J, Lau A, Valge-Archer V, Byers LA, Barry ST, Heymach JV. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell, 2025. e-Pub 2025. PMID: 40645185.
16. Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell 43(6):1125-1140.e10, 2025. e-Pub 2025. PMID: 40345189.
17. Li, H, Salehjahromi, M, Godoy, M, Qin, K, Plummer, CM, Zhang, Z, Hong, L, Heeke, S, Le, X, Vokes, N, Zhang, B, Araujo, HA, Altan, M, Wu, CC, Antonoff, MB, Ostrin, EJ, Gibbons, DL, Heymach, JV, Lee, JJ, Gerber, DE, Wu, J, Zhang, J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers 17(9), 2025. e-Pub 2025. PMID: 40361426.
18. Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O'Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA, Gay CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40126456.
19. Vailati Negrao, M, Paula, AG, Molkentine, D, Hover, LD, Nilsson, M, Vokes, N, Engstrom, LD, Calinisan, A, Briere, DM, Waters, L, Hallin, J, Diao, L, Altan, M, Blumenschein, GR, Skoulidis, F, Wang, J, Kopetz, S, Hong, DS, Gibbons, DL, Olson, P, Christensen, JG, Heymach, JV. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical Cancer Research 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
20. Di Federico, A, Hong, L, Elkrief, A, Thummalapalli, R, Cooper, AJ, Ricciuti, B, Digumarthy, S, Alessi, JV, Gogia, P, Pecci, F, Makarem, M, Gandhi, M, Garbo, E, Saini, A, De Giglio, A, Favorito, V, Scalera, S, Cipriani, L, Marinelli, D, Haradon, D, Nguyen, T, Haradon, J, Voligny, E, Vaz, VR, Gelsomino, F, Sperandi, F, Melotti, B, Ladanyi, M, Zhang, J, Gibbons, DL, Heymach, JV, Nishino, M, Lindsay, J, Rodig, SJ, Pfaff, KL, Sholl, LM, Wang, X, Johnson, BE, Jänne, PA, Rekhtman, N, Maugeri-Saccà, M, Heist, RS, Ardizzoni, A, Awad, MM, Arbour, KC, Schoenfeld, AJ, Vokes, N, Luo, J. Lung adenocarcinomas with mucinous histology. Annals of Oncology 36(3):297-308, 2025. e-Pub 2025. PMID: 39637943.
21. Cooper, AJ, Arfe, A, Ricciuti, B, Gagné, A, Sholl, LM, Di Federico, A, Awad, MM, Aldea, M, Ghigna, MR, Grecea, M, Clark, P, Chaft, JE, Kris, MG, Riely, GJ, Rudin, CM, Dagogo-Jack, I, Mino-Kenudson, M, Hong, L, Kalhor, N, Vokes, N, Bowman, AS, Yang, SR, Rekhtman, N, Schoenfeld, AJ. Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors. JTO Clinical and Research Reports 6(1), 2025. e-Pub 2025. PMID: 39802817.
22. Altan, M, Li, R, Li, Z, Chen, R, Sheshadri, A, Tran, HT, Little, L, Baguley, J, Sinson, JC, Vokes, N, Gandhi, S, Antonoff, MB, Swisher, SG, Lizee, GA, Reuben, A, Heymach, JV, Zhang, J. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. Journal for immunotherapy of cancer 12(12), 2024. e-Pub 2024. PMID: 39721752.
23. Tarantino G, Ricker CA, Wang A, Ge W, Aprati TJ, Huang AY, Madha S, Chen J, Shi Y, Glettig M, Feng CH, Frederick DT, Freeman S, Holovatska MM, Manos MP, Zimmer L, Rosch A, Zaremba A, Livingstone E, Jameson JC, Saghafian S, Lee A, Zhao K, Morris LGT, Reardon B, Park J, Elmarakeby HA, Schilling B, Giobbie-Hurder A, Vokes NI, Buchbinder EI, Flaherty KT, Haq R, Wu CJ, Boland GM, Hodi FS, Van Allen EM, Schadendorf D, Liu D. Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma. Sci Adv 10(48):eadp4670, 2024. e-Pub 2024. PMID: 39602539.
24. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
25. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A Jr, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res 30(20):4743-4754, 2024. e-Pub 2024. PMID: 39150543.
26. Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
27. Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun 15(1):3152, 2024. e-Pub 2024. PMID: 38605064.
28. Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med 5(3):101463, 2024. e-Pub 2024. PMID: 38471502.
29. Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2024. e-Pub 2024. PMID: 38357092.
30. Tran HT, Heeke S, Sujit S, Vokes N, Zhang J, Aminu M, Lam VK, Vaporciyan A, Swisher SG, Godoy MCB, Cascone T, Sepesi B, Gibbons DL, Wu J, Heymach JV. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Ann Oncol 35(2):183-189, 2024. e-Pub 2024. PMID: 37992871.
31. Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42(2):225-237.e5, 2024. e-Pub 2024. PMID: 38278149.
32. Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang J. Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473297.
33. Caswell, DR, Gui, P, Mayekar, MK, Law, EK, Pich, O, Bailey, C, Boumelha, J, Kerr, DL, Blakely, CM, Manabe, T, Martínez-Ruiz, C, Bakker, B, De Dios Palomino Villcas, J, Vokes, N, Dietzen, M, Angelova, M, Gini, B, Tamaki, W, Allegakoen, P, Wu, W, Humpton, TJ, Hill, W, Tomaschko, M, Lu, WT, Haderk, F, Al-Bakir, M, Nagano, A, Gimeno-Valiente, F, de Carné Trécesson, S, Vendramin, R, Barbe, V, Mugabo, M, Weeden, CE, Rowan, AJ, McCoach, CE, Almeida, B, Green, M, Gomez, C, Nanjo, S, Barbosa, D, Moore, C, Przewrocka, J, Black, JR, Gronroos, E, Suárez-Bonnet, A, Priestnall, SL, Zverev, C, Lighterness, S, Cormack, J, Olivas, V, Cech, L, Andrews, T, Rule, B, Jiao, Y, Zhang, X, Ashford, P, Durfee, C, Venkatesan, S, Temiz, NA, Tan, L, Larson, LK, Argyris, PP, Brown, WL, Yu, EA, Rotow, JK, Guha, U, Roper, N, Yu, J, Vogel, RI, Thomas, NJ, Marra, A, Selenica, P, Yu, HA, Bakhoum, SF, Chew, SK, Reis-Filho, JS, Jamal-Hanjani, M, Vousden, KH, Mcgranahan, N, Van Allen, EM, Kanu, N, Harris, RS, Downward, J, Bivona, T, Swanton, C. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nature Genetics 56(1):60-73, 2024. e-Pub 2024. PMID: 38049664.
34. Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clin Cancer Res 29(21):4408-4418, 2023. e-Pub 2023. PMID: 37432985.
35. Al-Tashi Q, Saad MB, Sheshadri A, Wu CC, Chang JY, Al-Lazikani B, Gibbons C, Vokes NI, Zhang J, Lee JJ, Heymach JV, Jaffray D, Mirjalili S, Wu J. SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancers. Patterns (N Y) 4(8):100777, 2023. e-Pub 2023. PMID: 37602223.
36. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
37. Boiarsky, D, Lydon, C, Chambers, E, Sholl, LM, Nishino, M, Skoulidis, F, Heymach, JV, Luo, J, Awad, MM, Jänne, PA, Van Allen, EM, Barbie, DA, Vokes, N. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Annals of Oncology 34(7):589-604, 2023. e-Pub 2023. PMID: 37121400.
38. Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Panda A, Fang J, Skoulidis F, Wistuba II, Verma S, Merghoub T, Wolchok JD, Wong KK, DeBerardinis RJ, Minna JD, Vokes NI, Meador CB, Gainor JF, Wang L, Reuben A, Heymach JV. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell 41(7):1363-1380.e7, 2023. e-Pub 2023. PMID: 37327788.
39. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
40. Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet 55(5):807-819, 2023. e-Pub 2023. PMID: 37024582.
41. Boiarsky D, Lydon CA, Chambers ES, Sholl LM, Nishino M, Skoulidis F, Heymach JV, Luo J, Awad MA, Janne PA, Van Allen EM, Barbie DA, Vokes NI. Molecular markers of metastatic disease in KRAS mutant lung adenocarcinoma. Annals of Oncology, 2023. e-Pub 2023.
42. Nishino M, Lu J, Hino T, Vokes NI, Jänne PA, Hatabu H, Johnson BE. Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. J Thorac Imaging, 2023. e-Pub 2021. PMID: 34524205.
43. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
44. Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Treviño S, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV. ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC. Clin Cancer Res 29(23):4958-4972, 2023. e-Pub 2023. PMID: 37733794.
45. Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14:1322818, 2023. e-Pub 2023. PMID: 38152395.
46. Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver N, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, Team D, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612278.
47. Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol 8(8):1160-1168, 2022. e-Pub 2022. PMID: 35708671.
48. Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884533.
49. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
50. Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA. Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma. J Thorac Oncol 17(6):779-792, 2022. e-Pub 2022. PMID: 35331964.
51. Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Rizvi H, Egger J, Plodkowski AJ, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Altan M, Heymach JV, Skoulidis F, Gainor JF, Hellmann MD, Awad MM. Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status. J Thorac Oncol 17(3):399-410, 2022. e-Pub 2022. PMID: 34740862.
52. Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan CL, Sethunath V, Carvalho FLF, Imamovic A, Ricker C, Vokes NI, Nyman J, Berchuck JE, Park J, Hirsch MS, Haq R, Mary Lee GS, McGregor BA, Chang SL, Feldman AS, Wu CJ, McDermott DF, Heng DYC, Signoretti S, Van Allen EM, Choueiri TK, Viswanathan SR. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep 38(1):110190, 2022. e-Pub 2022. PMID: 34986355.
53. Nishino M, Lu J, Hino T, Vokes NI, Jänne PA, Hatabu H, Johnson BE. Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precis Oncol 5(5):1603-1610, 2021. e-Pub 2021. PMID: 34994646.
54. Reardon, B, Moore, ND, Moore, NS, Kofman, E, AlDubayan, SH, Cheung, AT, Conway, J, Elmarakeby, H, Imamovic, A, Kamran, SC, Keenan, T, Keliher, D, Konieczkowski, DJ, Liu, D, Mouw, KW, Park, J, Vokes, N, Dietlein, F, Van Allen, EM. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nature Cancer 2(10):1102-1112, 2021. e-Pub 2021. PMID: 35121878.
55. Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 39(5):649-661.e5, 2021. e-Pub 2021. PMID: 33711272.
56. He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EM. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med 27(3):426-433, 2021. e-Pub 2021. PMID: 33664492.
57. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346-360.e7, 2021. e-Pub 2021. PMID: 33482121.
58. Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 12(1):808, 2021. e-Pub 2021. PMID: 33547292.
59. Conway JR, Dietlein F, Taylor-Weiner A, AlDubayan S, Vokes N, Keenan T, Reardon B, He MX, Margolis CA, Weirather JL, Haq R, Schilling B, Stephen Hodi F, Schadendorf D, Liu D, Van Allen EM. Integrated molecular drivers coordinate biological and clinical states in melanoma. Nat Genet 52(12):1373-1383, 2020. e-Pub 2020. PMID: 33230298.
60. Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, Margolis CA, Vokes NI, Du H, Shukla SA, Cherniack AD, Sonpavde G, Haddad RI, Awad MM, Giannakis M, Hodi FS, Liu XS, Signoretti S, Kadoch C, Freedman ML, Kwiatkowski DJ, Van Allen EM, Choueiri TK. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res 8(8):1075-1084, 2020. e-Pub 2020. PMID: 32321774.
61. Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes NI, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med 25(12):1916-1927, 2019. e-Pub 2019. PMID: 31792460.
62. Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 31832578.
63. Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 50(9):1271-1281, 2018. e-Pub 2018. PMID: 30150660.
64. Lewis CA, Parker SJ, Fiske BP, McCloskey D, Gui DY, Green CR, Vokes NI, Feist AM, Vander Heiden MG, Metallo CM. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol Cell 55(2):253-63, 2014. e-Pub 2014. PMID: 24882210.
65. Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM, Vokes NI, Guarente L, Vander Heiden MG, Stephanopoulos G. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. Nat Commun 4:2236, 2013. e-Pub 2013. PMID: 23900562.
66. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43(9):869-74, 2011. e-Pub 2011. PMID: 21804546.
67. Vokes NI, Bailey JM, Rhodes KV. "Should I give you my smoking lecture now or later?" Characterizing emergency physician smoking discussions and cessation counseling. Ann Emerg Med 48(4):406-14, 414.e1-7, 2006. e-Pub 2006. PMID: 16997676.

Review Articles

1. Bao R, Hutson A, Madabhushi A, Jonsson VD, Rosario SR, Barnholtz-Sloan JS, Fertig EJ, Marathe H, Harris L, Altreuter J, Chen Q, Dignam J, Gentles AJ, Gonzalez-Kozlova E, Gnjatic S, Kim E, Long M, Morgan M, Ruppin E, Valen DV, Zhang H, Vokes N, Meerzaman D, Liu S, Van Allen EM, Xing Y. Ten challenges and opportunities in computational immuno-oncology. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39461879.
2. Zhang J, Vokes N, Li M, Xu J, Bai H, Wang J, Wang Z, Zhang J. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment. Chin Med J Pulm Crit Care Med 2(3):151-161, 2024. e-Pub 2024. PMID: 39403414.
3. Wang X, Lamberti G, Di Federico A, Alessi J, Ferrara R, Sholl ML, Awad MM, Vokes N, Ricciuti B. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann Oncol 35(6):508-522, 2024. e-Pub 2024. PMID: 38537779.
4. Al-Tashi Q, Saad MB, Muneer A, Qureshi R, Mirjalili S, Sheshadri A, Le X, Vokes NI, Zhang J, Wu J. Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review. Int J Mol Sci 24(9), 2023. e-Pub 2023. PMID: 37175487.
5. Vokes NI, Pan K, Le X. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. Ther Adv Med Oncol 15:17588359231161409, 2023. e-Pub 2023. PMID: 36950275.
6. Vokes NI, Zhang J. The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers. Lung Cancer (Auckl) 12:139-149, 2021. e-Pub 2021. PMID: 34880699.
7. Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, Vokes NI, Stephanopoulos G, Cantley LC, Metallo CM, Locasale JW. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol 76:325-34, 2011. e-Pub 2011. PMID: 22262476.

Other Articles

1. Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 43(6):1177-1179, 2025. PMID: 40494276.
2. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 639(8054):E19, 2025. PMID: 40016449.
3. Vokes NI Giving up surgery. Ann Intern Med 157(11):829-30, 2012. PMID: 23208172.

Editorials

1. Vokes NI, Le X, Yap TA. PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC. Clin Cancer Res 30(18):3968-3970, 2024. PMID: 39018064.
2. Vokes NI, Van Allen EM. Tumor Evolution: A Problem of Histocompatibility. Cell 171(6):1252-1253, 2017. PMID: 29195070.
3. Vokes NI, Jänne PA. Resistance in trans-ition. J Thorac Oncol 12(11):1608-1610, 2017. PMID: 29074207.
4. Liu D, Vokes NI, Van Allen EM. Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discov 7(6):555-557, 2017. PMID: 28576842.

Abstracts

1. Santo V, Elkrief A, Concannon K, Federico AD, Gandhi MM, Pecci F, Garbo E, Gariazzo E, Paoloni F, Aldea M, Sholl LM, Rodig S, Schoenfeld AJ, Vokes NI, Ricciuti B. Differential predictive impact of PD-L1 expression on immunotherapy outcomes and immunophenotype in squamous versus non-squamous NSCLC. ASCO Annual Meeting, 2025. e-Pub 2025.
2. Gariazzo E, Elkrief A, Concannon K, Metro G, Dodi A, Favorito V, Santo V, Pecci F, Aldea M, Garbo E, LoPiccolo J, Paoloni F, Nishino M, Sholl LM, Florez N, Cipriani L, Vokes NI, Schoenfeld AJ, Ricciuti B. Clinical outcomes and predictors of response to PD-(L) 1 blockade in patients with oncogene-driver negative NSCLC who have never smoked. ASCO Annual Meeting, 2025. e-Pub 2025.
3. Boiarsky D, Hong L, Cooper AJ, Ricciuti B, Saad MB, Elkrief A, Federico AD, Aminu M, Rinsurongkawong W, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Heymach J, Wu J, Awad MM, Schoenfeld AJ, Zhang J, Vokes NI. Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy. ASCO Annual Meeting, 2025. e-Pub 2025.
4. Azizi A, Ravi A, Capelletti M, Haradhvala N, Vokes N, Sammut S, Ressler S, Radovich M, Gainor J, Getz G. Non-synonymous mutations in the IFN-γ pathway are predictive of response to immune checkpoint inhibition in NSCLC. AACR Annual Meeting, 2025. e-Pub 2025.
5. Negrao MV, Paula AG, Molkentine D, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters L, Hallin J, Diao L, Altan M, Blumenschein GR, Skoulidis F, Wang J, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen JG, Heymach JV. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. AACR Annual Meeting, 2025. e-Pub 2025.
6. Saad MB, Al-Tashi Q, Hong L, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter B, Cascone T, Le X, Chang J, Gibbons DL, Vaporciyan AA, Lee J, Mirjalili S, Jaffray DA, Gainor JF, Lou Y, Ricciuti B, DiFederico A, Pecci F, Awad MM, Heymach JV, Vokes NI, Zhang J, Wu J. Machine learning-based clinico-genomic prediction of benefits to add chemotherapy to immunotherapy in metastatic non-small cell lung cancer. SITC, 2024. e-Pub 2024.
7. Trevino S, Chen H, Halliday A, Ren X, Du R, Hong L, Poteete A, Zhu B, Nilsson M, Aminu M, Rinsurongkawong W, Rinsurongkawong V, Lee J, Blumenschein G, Gay C, Negrao MV, Altan M, Cascone T, Elamin Y, Skoulidis F, Tran H, Antonoff M, Vaporciyan AA, Wu J, Kurie J, Gibbons DL, Zhang J, Heymach JV, Le X, Vokes NI. Defining immune and tumor resistant cell states to targeted vs immune therapy in non-small cell lung cancer (NSCLC). SITC, 2024. e-Pub 2024.
8. Salehjahromi M, Hong L, Li H, Kitsel Y, Godoy M, Wu CC, Antonoff M, Toumazis I, Ostrin E, Heeke S, Vokes NI, Le X, Vaporciyan AA, Lee J, Heymach JV, Zhang J, Wu J. Predicting lung cancer risk with CT radiomics: implications for immunoprevention. SITC, 2024. e-Pub 2024.
9. Saad MB, Al-Tashi Q, Hong L, Li W, Li S, Heymach JV, Lou Y, Vokes NI, Zhang J, Wu J. Estimating the Average Treatment Effect Using Weighting Methods in Lung Cancer Immunotherapy. International Workshop on Computational Mathematics Modeling in Cancer Analysis, 2024. e-Pub 2024.
10. Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Federico A, Aminu M, Rinsurongkawong W, Lewis J, Vaporciyan A, Le X, Lee JJ, Luo J, Wu J, Negaro M, Gibbons D, Heymach J, Skoulidis F, Schoenfeld A, Awad M, Zhang J, Vokes N. Machine Learning-Based Clinicogenomic Prediction of Response to PD-(L) 1 Inhibition in KRAS Altered Non-Small Cell Lung Cancer. WCLC, 2024. e-Pub 2024.
11. Hong L, Aminu M, Young C, Rinsurongkawong W, Li H, Qin K, Elamin Y, Sepesi B, Gibbons D, Vaporciyan A, Lee JJ, Roy-Chowdhuri S, Routbort M, Le X, Heymach J, Wu J, Zhang J, Vokes N. Clinicogenomic Profile of Different Resistance Patterns to Immune Checkpoint Inhibitors in NSCLC. WCLC, 2024. e-Pub 2024.
12. Ricciuti B, Hong L, Gariazzo E, Gorria T, Thummalapalli R, Awosika N, Mollica L, Citarella F, Gandhi M, Elkrief A, Pecci F, Alessi J, Federico A, Makarem M, Saini A, Aldea M, Garbo E, Espinar JB, Ferrara R, Alessio C, Pinato D, Schoenfeld A, Nana F, Mezquita L, Metro G, Vokes N, Awad M. Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade. WCLC, 2024. e-Pub 2024.
13. Boiarsky D, Hong L, Ricciuti B, Cooper AJ, Saad MB, Elkrief A, Federico AD, Aminu M, Rinsurongkawong W, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Heymach J, Wu J, Schoenfeld AJ, Awad MM, Zhang J, Vokes NI. Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer. ASCO Annual Meeting, 2024. e-Pub 2024.
14. Federico AD, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Shaverdian N, Ricciuti B, Machado Alessi JV, Giglio AD, Pecci F, Lamberti G, Gandhi MM, Sholl LM, Nishino M, Ardizzoni A, Heist RS, Arbour KC, Schoenfeld AJ, Vokes NI, Awad MM. TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma. ASCO Annual Meeting, 2024. e-Pub 2024.
15. Azizi A, Ravi A, Vokes N, Sammut S, Gainor J, Getz G. Increased immunotherapy sensitivity associated with damaging IFN-gamma pathway mutations in NSCLC. AACR Annual Meeting, 2024. e-Pub 2024.
16. Vokes N, Gandara D, Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Liu J, Giangreco N, Zhu O, Wipperman MF, McIntyre DA, Hamon S, Sun D, Wang F, Li S, Lowy I, Gullo G, Rietschel P, Pouliot J, Jankovic V. Circulating Tumor DNA (ctDNA) Dynamics and Survival Outcomes in Patients with Advanced NSCLC and High (> 50%) PD-L1 Expression, Randomized to Cemiplimab vs Chemotherapy. ASCO Annual Meeting, 2023. e-Pub 2023.
17. Aminu M, Vokes NI, Saad MB, Li H, Hong L, Mohamed MS, Boom J, Chen P, Altan M, Gandhi S, Swisher S, Antonoff MB, Pozadzides JV, Jr GB, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao AS, Tu J, Lee J, Zhang J, Heymach JV, Wu J. Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC. AACR Annual Meeting, 2023. e-Pub 2023.
18. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Tanimoto A, Novegil VY, Soto LS, Rocha PD, Vokes N, Gibbons D, Frumovitz M, Fujimoto J, Wang J, Glisson B, Byers LA, Gay CM. YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition. AACR Annual Meeting, 2023. e-Pub 2023.
19. Hong L, Aminu M, Lu X, Saad MB, Chen P, Rinsurongkawong W, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Roy-Chowdhuri S, Routbort MJ, Heymach JV, Wu J, Zhang J, Vokes NI. Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC. AACR Annual Meeting, 2023. e-Pub 2023.
20. Le X, Wang R, Vokes N, Elamin Y, Kalhor N, McGrail D, Xi Y, Treviño III S, Hong L, Du R, Blumenschein G, Gay C, Negrao M, Altan M, Tran H, Hu L, Wang J, Heeke S, Nilsson M, Robichaux J, Dang M, Han G, Byers LA, Tsao A, Sepesi B, Bernatchez C, Zhang J, Wang L, Heymach J. Enhanced lineage plasticity in RTK-independent TKI-resistant EGFR-mutant NSCLC. AACR Annual Meeting, 2022. e-Pub 2022.
21. Boiarsky D, Lydon CA, Chambers E, Janne PA, Awad MM, Van Allen EM, Barbie D, Vokes NI. Genomic correlates of metastasis in KRAS mutant lung adenocarcinoma. AACR Annual Meeting, 2022. e-Pub 2022.
22. Hong L, Rinsurongkawong W, Rinsurongkawong V, Spelman AR, Lewis J, Gandhi SJ, Antonoff MB, Gibbons DL, Vaporciyan AA, Lee JJ, Heymach JV, Zhang J, Vokes NI. 1328P Outcomes from local consolidative therapy and immune checkpoint inhibitors in metastatic non-small cell lung cancer. ESMO, 2021. e-Pub 2021.
23. Vokes NI, Nguyen T, Lydon C, Chambers E, Sholl L, Nishino M, Van Allen E, Janne P. Genomic Correlates of Differential Response to EGFR-Directed Tyrosine Kinase Inhibitors. AACR Annual Meeting, 2020. e-Pub 2020.
24. Vokes NI, Alguilar E, Adeni A, Umeton R, Sholl L, Rizvi H, Jänne P, Van Allen E, Hellmann M, Awad M. Standardization of tumor mutational burden (TMB) quantification and thresholds in NSCLC, 2019. e-Pub 2019.
25. Vokes NI, Margolis C, Liu D, Schilling B, Schadendorf D, Van Allen E. Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade, 2019. e-Pub 2019.
26. Vokes NI, Nguyen T, Lydon C, Chambers E, Sholl L, Nishino M, Van Allen E, Janne P. Genomic Correlates of Differential Response to EGFR-Directed Tyrosine Kinase Inhibitors, 2019. e-Pub 2019.
27. Vokes NI, Alguilar J, Adeni A. Efficacy and genomic correlates of response to anti-PD1/PD-L1 blockade in non-small cell lung cancers harboring targetable oncogenes, 2018. e-Pub 2018.
28. Vokes NI, Miao D, Margolis M. Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors, 2018. e-Pub 2018.
29. Vokes NI, Adamia S, Griffin J. Small non-coding RNAs as potential therapeutic agents for acute myeloid leukemia (AML), 2015. e-Pub 2015.
30. Boiarsky D, Hong L, Cooper AJ, Ricciuti B, Spurr L, Saad PhD MB, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong WR, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee J, Heymach JV, Wu J, Pitroda SP, Awad MM, Schoenfeld AM, Zhang J, Vokes NI. Identifying patients cured from metastatic non-small cell lung cancer with anti-PD-(L)1 therapy. IASLC WCLC.
31. Gouda MA, Xavier CB, Torrado C, Shah PA, Rai K, Vokes N, Alhalabi O, Bedford MT, Gao J, Majd NK, Li J, Javle M, Meric-Bernstam F, Rodon J. Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE database. ASCO Annual Meeting.
32. Vokes NI, Aminu M, Zhu B, Saad M, Li H, Hong L, Mohamed MQ, Altan M, Gandhi S, Solis Soto LM, Shi O, Rojas FR, Santiago Treviño III, Burns B, Swisher SG, Antonoff MB, Pozadzides JV, Jr GB, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao A, Tu J, Lee J, Wu J, Zhang J, Heymach JV. Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual Immune Checkpoint Inhibition or ICI-Chemotherapy. IASLC WCLC.

Book Chapters

1. Vokes, N, Awad, MM. Biomarkers. In: Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?, 27-54, 2021.